Swiss pharmaceutical enterprise group Nycomed (Nycomed) has announced the acquisition of Techpool Biochemical Pharmaceutical Co., Ltd. ("Temple") of 51.34% of the shares, significantly expanding its business in China. Prior to this Shanghai Medical Pharmaceutical Group Co., Ltd. ("the Pharmaceutical Group") in this transaction before the Temple of the largest shareholder, currently holds 40.8% stake in Temple. According to reports, a global pharmaceutical company Nycomed currently ranked 28, while the Temple is located in Guangdong Province, a fast-growing biopharmaceutical company specializing in the development of natural sources of bio-pharmaceutical sales. This and Purchase involving an amount of 2.14 billion U.S. dollars. Nycomed, senior vice president of North Asia, told reporters that Mr. Liu Youlei, which is Nycomed's first acquisition in China, in 2011 the company will benefit from access to more than 700 million in sales, 2012 In -2015, the company will achieve sales growth of 30% per year. With China's hospitals and the expansion of coverage of medical claims, the main Temple pharmaceutical products will remain stable and strong growth momentum. Bi Yuelun Nycomed CEO, said: "The acquisition of a majority stake in Temple provides us a unique opportunity, so we have the opportunity in China --- the world's fastest growing pharmaceutical markets in the world to enhance our Business operations. Temple's unique franchise model and Nycomed's product development strategy of highly complementary, and will be expanding our business in emerging markets, the cornerstone. "

Previous: Shopping to eat takeout in China by express high temperature thermal reminder
Next： Mellow Vienna: Coffee will not take away